ArticleCancer management and research2021

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.

Ying-Tao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.